Clinical trial · Observational
Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
A Retrospective Observational Cohort Study Evaluating the Association Between Concomitant Beta-blocker Exposure and Clinical Outcomes of Standard Anti-PD-1/PD-L1 Therapy in Advanced Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective real-world cohort study evaluated whether concomitant long-term beta-blocker exposure during routine clinical care was associated with clinical outcomes in patients with advanced NSCLC who received standard anti-PD-1/PD-L1 inhibitor therapy. Patients were categorized according to documented concomitant long-term beta-blocker exposure during the treatment course. Clinical outcomes, including progression-free survival, objective response rate, and overall survival, were compared between exposure groups. This was a non-interventional observational study; anti-PD-1/PD-L1 treatment and beta-blocker use were determined by routine clinical practice rather than by the study protocol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-PD-1/PD-L1 Therapy (Standard of Care) | Drug | — | UNRESOLVED |
| Beta-blocker (Concomitant Exposure) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Standard Anti-PD-1/PD-L1 Therapy Without Long-term Beta-blocker Exposure
- description
- Patients with advanced NSCLC who received standard anti-PD-1/PD-L1 inhibitor therapy during routine clinical care and had no documented long-term beta-blocker exposure during the relevant treatment period.
- interventionNames
- Drug: Anti-PD-1/PD-L1 Therapy (Standard of Care)
- label
- Standard Anti-PD-1/PD-L1 Therapy With Concomitant Long-term Beta-blocker Exposure
- description
- Patients with advanced NSCLC who received standard anti-PD-1/PD-L1 inhibitor therapy during routine clinical care and had documented concomitant long-term beta-blocker exposure during the relevant treatment period. Beta-blockers were prescribed for routine clinical indications and were not assigned by the study protocol.
- interventionNames
- Drug: Anti-PD-1/PD-L1 Therapy (Standard of Care)
- Drug: Beta-blocker (Concomitant Exposure)
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older; * Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer; * Received standard anti-PD-1/PD-L1 inhibitor therapy during routine clinical care; * Available baseline clinical records and follow-up data sufficient for assessment of treatment exposure and clinical outcomes; Exclusion Criteria: * Incomplete baseline clinical records or follow-up data that preclude assessment of treatment exposure or clinical outcomes; * Concomitant participation in an interventional therapeutic clinical trial affecting the same treatment course, if applicable; * Other major clinical conditions or competing malignancies that preclude valid outcome assessment, according to the prespecified study protocol
References
Publications (0)
Data not yet available